UK Edition
AdvertiseSubmit Company
Pharma JournalEvidence-Based Pharmaceutical Intelligence
BIOTECHNOLOGY

argenx

A

argenx

BiotechnologyGhent, Belgium
Visit Website

About argenx

argenx built its reputation on a single, unusually productive starting point: the immune systems of llamas and other camelids, which produce a class of antibodies that proved to be a powerful foundation for engineering next-generation immunology medicines. From that scientific premise, the Belgian-American company has grown into one of the most closely watched names in immunology drug development, with a commercial product, VYVGART (efgartigimod alfa), approved in multiple markets for the treatment of generalised myasthenia gravis.

Founded in 2008 and headquartered in Ghent, Belgium, with significant operations in the United States and Japan, argenx is listed on Nasdaq (ARGX) and on Euronext Brussels, reflecting its transatlantic scope. The company's pipeline is centred on FcRn biology, targeting the neonatal Fc receptor to reduce disease-causing IgG antibodies in a range of serious autoimmune conditions. This mechanism underpins efgartigimod in several additional indications under investigation, as well as other early-stage programmes in the portfolio.

The company operates with a focused autoimmune disease strategy rather than pursuing broad therapeutic diversification, concentrating resources on conditions where dysregulated IgG antibodies drive pathology. Target areas include neuromuscular disease, haematology, and dermatology, among others under active clinical investigation.

Further information is available at argenx.com.

Similar Companies

More in Biotechnology

E

Emergex

Emergex Vaccines is a UK-based clinical-stage biotechnology company developing a new class of synthetic peptide vaccines designed to stimulate cytotoxic T-lymphocyte (CTL) responses rather than the antibody-driven immunity targeted by conventional vaccines. Founded in 2015 and headquartered in Abingdon, Oxfordshire, the company was established on the premise that T-cell immunity offers broader and more durable protection against rapidly mutating viral pathogens, including pandemic influenza strains and other emerging infectious threats. Platform Technology and Pipeline The company's core platform centres on short synthetic peptide constructs derived from conserved viral protein sequences. Because these sequences change little across viral variants, the approach aims to produce vaccines with cross-strain efficacy, addressing a central limitation of seasonal influenza vaccines that must be reformulated annually. Emergex has advanced candidates targeting influenza A and dengue fever through early-phase clinical evaluation, with additional programmes directed at other flaviviruses and respiratory viruses. Development and Funding Background Emergex has received support from UK public funding bodies and private investors to progress its pipeline from pre-clinical research into Phase I clinical trials. The company operates under a largely asset-light model, collaborating with contract research organisations and academic partners to conduct clinical work. As a private company, Emergex does not carry a public stock listing. Its programmes are positioned within the broader landscape of next-generation vaccine development, addressing unmet needs in both seasonal infectious disease management and pandemic preparedness. Further information is available at emergexvaccines.com.

View profile
R

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals built one of the most productive drug-discovery engines in the industry, turning its proprietary VelociSuite technology platform into a stream of approved medicines across immunology, oncology, ophthalmology, and rare disease. VelociSuite: The Engine Behind the Pipeline Founded in 1988 and headquartered in Tarrytown, New York, Regeneron developed VelociSuite as a set of integrated technologies for generating fully human antibodies at speed and scale. VelocImmune, the flagship component, replaced mouse immune systems with human equivalents, dramatically improving the translatability of antibody candidates from preclinical work into clinical development. This approach underpins the majority of Regeneron's approved portfolio and its extensive collaboration pipeline. Approved Portfolio and Collaboration Network The company's commercial portfolio includes treatments for atopic dermatitis, asthma, chronic sinusitis with nasal polyps, high cholesterol, wet age-related macular degeneration, diabetic eye disease, cervical cancer, and rare blood disorders, among other indications. Dupixent, co-developed and co-commercialised with Sanofi, became one of the best-selling medicines globally and continues to be studied across a broad range of type 2 inflammatory conditions. Eylea, targeting vascular endothelial growth factor, remains a leading treatment in retinal disease. Regeneron's long-standing alliance with Sanofi covers immunology and oncology, while the company maintains an oncology collaboration with Bayer centred on cancer therapy. The company also operates Regeneron Genetics Center, one of the largest human genetics programmes in the world, partnering with health systems to sequence patient genomes and identify novel drug targets. Listed on Nasdaq under the ticker REGN, Regeneron employs tens of thousands of people globally, with significant research and manufacturing infrastructure concentrated in New York State. Further information is available at regeneron.com.

View profile
B

Biogen

Biogen pioneered the neuroscience field as one of the world's oldest independent biotechnology companies, founded in 1978 by a group of distinguished scientists including Nobel laureate Walter Gilbert. Headquartered in Cambridge, Massachusetts, the company has spent nearly five decades focused almost exclusively on neurological and neurodegenerative diseases, a level of specialisation that sets it apart from diversified pharma peers. Neuroscience Focus and Key Therapy Areas Biogen's portfolio centres on multiple sclerosis, where it holds one of the broadest treatment ranges in the industry, spanning injectable, oral, and infusion therapies. The company also works in spinal muscular atrophy, Alzheimer's disease, Parkinson's disease, and rare neurological conditions. Its partnership with Eisai produced lecanemab (marketed as Leqembi), an Alzheimer's treatment that received traditional FDA approval in 2023, marking a significant moment in a field that had seen decades of clinical setbacks. Global Scale and Commercial Presence Listed on the Nasdaq under the ticker BIIB, Biogen operates across more than 30 countries, with commercial infrastructure spanning North America, Europe, and Asia Pacific. The company invests heavily in research and development as a proportion of revenue, consistent with its identity as a science-led organisation rather than a marketing-driven one. Its biosimilars division, built through a long-standing collaboration with Samsung Bioepis, gives Biogen a commercial presence in the cost-sensitive biologics market alongside its branded neurology pipeline. Biogen has also expanded into rare disease and neuropsychiatry, reflecting a strategic effort to broaden the neuroscience platform beyond multiple sclerosis as the MS market faces increasing genericisation. The company's gene therapy interests, including assets in-licensed and acquired over recent years, signal further ambition in treating diseases at the molecular level. For professionals in pharmaceutical, biotech, and medical research sectors, Biogen represents one of the most focused large-cap neuroscience organisations operating globally. Further information is available at biogen.com.

View profile
AdvertisementTeksyte LTD

List Your Company

Showcase your company to thousands of pharma professionals.

Submit Listing

Advertise With Us

Reach decision-makers in the pharmaceutical industry.

Learn More

We use cookies and analytics to understand how the site is used and to keep the service free. Choose Accept All to allow this, or Essential Only to use just the cookies we need to keep the site working. You can change your choice any time in our Cookie Policy